Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 12—December 2024
Research

Clinical Manifestations, Antifungal Drug Susceptibility, and Treatment Outcomes for Emerging Zoonotic Cutaneous Sporotrichosis, Thailand

Pattriya Jirawattanadon, Sumanas Bunyaratavej, Charussri Leeyaphan, Piriyaporn Chongtrakool, Panitta Sitthinamsuwan, Waratchaya Panjapakkul, Suthasanee Prasertsook, Phuwakorn Saengthong-aram, Nicha Wareesawetsuwan, Julaluck Posri, and Penvadee PattanaprichakulComments to Author 
Author affiliation: Siriraj Hospital Faculty of Medicine, Bangkok, Thailand

Main Article

Table 5

Comparison of hazard ratios for time-to-improvement and time-to-cure among patients in study of clinical manifestations, antifungal drug susceptibility, and treatment outcomes for emerging zoonotic cutaneous sporotrichosis, Thailand*

Variables Time-to-improvement†
 Time-to-cure
Univariate analysis
 Univariate analysis
 Multivariate analysis
Crude HR (95% CI) p value Crude HR (95% CI) p value Adjusted HR‡ (95% CI) p value
Patient sex
M Referent 0.452
 Referent 0.102
 Referent 0.620
F
 1.3 (0.7–2.5)
1.8 (0.9–3.7)
1.9 (0.9–4.1)
Patient age at diagnosis, y
<60 Referent 0.587
 Referent 0.176
 Referent 0.109
>60
 1.2 (0.7–2.1)
1.5 (0.8–2.9)
1.7 (0.9–3.1)
Immunologic status
Immunocompromised 1.5 (0.7–3.4) 0.299
 0.8 (0.4–2.0) 0.686
 NA
Immunocompetent
 Referent
Referent
NA
Cat exposure
Yes 0.9 (0.5–1.7) 0.648
 0.7 (0.4–1.4) 0.349
 NA
No
 Referent
Referent
NA
Lesions
Single Referent 0.253
 Referent 0.761
 NA
Multiple
 0.7 (0.4–1.3)
1.1 (0.6–2.1)
NA
Morphology
Nonpustular Referent 0.445
 Referent 0.448
 NA
Pustular
 0.8 (0.4–1.5)
1.3 (0.7–2.5)
NA
Arrangement
Lymphocutaneous pattern 0.9 (0.5–1.8) 0.773 1.2 (0.6–2.3) 0.559 NA
Lymphadenopathy
 0.9 (0.6–2.4)
 0.895
2.6 (0.9–7.1)
 0.086
2.7 (1.0–7.5)
 0.106
Itraconazole susceptibility§
MIC <1 μg/mL Referent 0.735 Referent 0.998 NA
MIC = 1 μg/mL 1.3 (0.3–5.9) 1.1 (0.2–4.3) NA

*HRs were calculated by using the Cox proportional hazard model. HR, hazard ratio; NA, not applicable. †Multivariate analysis was not performed for time-to-improvement variables. ‡Adjusted for patient age and sex. §Itraconazole susceptibility tests were performed for specimens from 9 patients. A cutoff point of 1 μg/mL was used according to a previous study relating the itraconazole MIC to clinical outcomes (26).

Main Article

References
  1. Lopes-Bezerra  LM, Schubach  A, Costa  RO. Sporothrix schenckii and sporotrichosis. An Acad Bras Cienc. 2006;78:293–308. DOIPubMedGoogle Scholar
  2. Mahajan  VK. Sporotrichosis: an overview and therapeutic options. Dermatol Res Pract. 2014;2014:272376. DOIPubMedGoogle Scholar
  3. Rodrigues  AM, Bagagli  E, de Camargo  ZP, Bosco  SM. Sporothrix schenckii sensu stricto isolated from soil in an armadillo’s burrow. Mycopathologia. 2014;177:199–206. DOIPubMedGoogle Scholar
  4. Orofino-Costa  R, Macedo  PM, Rodrigues  AM, Bernardes-Engemann  AR. Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics. An Bras Dermatol. 2017;92:606–20. DOIPubMedGoogle Scholar
  5. Bonifaz  A, Saúl  A, Paredes-Solis  V, Fierro  L, Rosales  A, Palacios  C, et al. Sporotrichosis in childhood: clinical and therapeutic experience in 25 patients. Pediatr Dermatol. 2007;24:369–72. DOIPubMedGoogle Scholar
  6. Paixão  AG, Galhardo  MCG, Almeida-Paes  R, Nunes  EP, Gonçalves  MLC, Chequer  GL, et al. The difficult management of disseminated Sporothrix brasiliensis in a patient with advanced AIDS. AIDS Res Ther. 2015;12:16. DOIPubMedGoogle Scholar
  7. Werner  AH, Werner  BE. Sporotrichosis in man and animal. Int J Dermatol. 1994;33:692–700. DOIPubMedGoogle Scholar
  8. Quintal  D. Sporotrichosis infection on mines of the Witwatersrand. J Cutan Med Surg. 2000;4:51–4. DOIPubMedGoogle Scholar
  9. Centers for Disease Control (CDC). Multistate outbreak of sporotrichosis in seedling handlers, 1988. MMWR Morb Mortal Wkly Rep. 1988;37:652–3.PubMedGoogle Scholar
  10. Anderson  PC. Cutaneous sporotrichosis. Am Fam Physician. 1983;27:201–4.PubMedGoogle Scholar
  11. Mahmoudi  S, Zaini  F. Sporotrichosis in Iran: A mini review of reported cases in patients suspected to cutaneous leishmaniasis. Curr Med Mycol. 2015;1:39–45. DOIPubMedGoogle Scholar
  12. Kazemi  A, Razi  A. Sporotrichosis in Iran. Rev Iberoam Micol. 2007;24:38–40. DOIPubMedGoogle Scholar
  13. Gremião  IDF, Miranda  LHM, Reis  EG, Rodrigues  AM, Pereira  SA. Zoonotic epidemic of sporotrichosis: cat to human transmission. PLoS Pathog. 2017;13:e1006077. DOIPubMedGoogle Scholar
  14. Lyon  GM, Zurita  S, Casquero  J, Holgado  W, Guevara  J, Brandt  ME, et al.; Sporotrichosis in Peru Investigation Team. Population-based surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis in Peru. Clin Infect Dis. 2003;36:34–9. DOIPubMedGoogle Scholar
  15. de Lima Barros  MB, de Oliveira Schubach  A, Galhardo  MC, Schubach  TM, dos Reis  RS, Conceição  MJ, et al. Sporotrichosis with widespread cutaneous lesions: report of 24 cases related to transmission by domestic cats in Rio de Janeiro, Brazil. Int J Dermatol. 2003;42:677–81. DOIPubMedGoogle Scholar
  16. Barros  MB, Schubach  AO, do Valle  AC, Gutierrez Galhardo  MC, Conceição-Silva  F, Schubach  TM, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004;38:529–35. DOIPubMedGoogle Scholar
  17. Fleury  RN, Taborda  PR, Gupta  AK, Fujita  MS, Rosa  PS, Weckwerth  AC, et al. Zoonotic sporotrichosis. Transmission to humans by infected domestic cat scratching: report of four cases in São Paulo, Brazil. Int J Dermatol. 2001;40:318–22.PubMedGoogle Scholar
  18. Kovarik  CL, Neyra  E, Bustamante  B. Evaluation of cats as the source of endemic sporotrichosis in Peru. Med Mycol. 2008;46:53–6. DOIPubMedGoogle Scholar
  19. Schubach  AO, Schubach  TM, Barros  MB. Epidemic cat-transmitted sporotrichosis. N Engl J Med. 2005;353:1185–6. DOIPubMedGoogle Scholar
  20. Reis  RS, Almeida-Paes  R, Muniz  MM, Tavares  PM, Monteiro  PC, Schubach  TM, et al. Molecular characterisation of Sporothrix schenckii isolates from humans and cats involved in the sporotrichosis epidemic in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz. 2009;104:769–74. DOIPubMedGoogle Scholar
  21. Mercurio  MG, Elewski  BE. Therapy of sporotrichosis. Semin Dermatol. 1993;12:285–9.PubMedGoogle Scholar
  22. Barros  MB, de Almeida Paes  R, Schubach  AO. Sporothrix schenckii and Sporotrichosis. Clin Microbiol Rev. 2011;24:633–54. DOIPubMedGoogle Scholar
  23. Freitas  DFS, de Siqueira Hoagland  B, do Valle  ACF, Fraga  BB, de Barros  MB, de Oliveira Schubach  A, et al. Sporotrichosis in HIV-infected patients: report of 21 cases of endemic sporotrichosis in Rio de Janeiro, Brazil. Med Mycol. 2012;50:170–8. DOIPubMedGoogle Scholar
  24. Sizar  O, Talati  R. Sporotrichosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023
  25. Fichman  V, Almeida-Silva  F, Francis Saraiva Freitas  D, Zancopé-Oliveira  RM, Gutierrez-Galhardo  MC, Almeida-Paes  R. Severe sporotrichosis caused by Sporothrix brasiliensis: antifungal susceptibility and clinical outcomes. J Fungi (Basel). 2022;9:49. DOIPubMedGoogle Scholar
  26. Marimon  R, Serena  C, Gené  J, Cano  J, Guarro  J. In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother. 2008;52:732–4. DOIPubMedGoogle Scholar
  27. Indoung  S, Chanchayanon  B, Chaisut  M, Buapeth  KO, Morteh  R, Jantrakajorn  S. Feline sporotrichosis caused by Sporothrix schenckii sensu stricto in Southern Thailand: phenotypic characterization, molecular identification, and antifungal susceptibility. Med Mycol. 2022;60:myac075. DOIPubMedGoogle Scholar
  28. Dropulic  LK, Lederman  HM. Overview of infections in the immunocompromised host. Microbiol Spectr. 2016;4:4.4.43. DOIPubMedGoogle Scholar
  29. Tovikkai  D, Maitrisathit  W, Srisuttiyakorn  C, Vanichanan  J, Thammahong  A, Suankratay  C. Sporotrichosis: The case series in Thailand and literature review in Southeast Asia. Med Mycol Case Rep. 2020;27:59–63. DOIPubMedGoogle Scholar
  30. Kwangsukstith  C, Vanittanakom  N, Khanjanasthiti  P, Uthammachai  C. Cutaneous sporotrichosis in Thailand: first reported case. Mycoses. 1990;33:513–7. DOIPubMedGoogle Scholar
  31. Taninratapat  N, Srisuttiyakorn  C. Localized cutaneous sporotrichosis on face in healthy Thai female. Mycopathologia. 2019;184:539–42. DOIPubMedGoogle Scholar
  32. Queiroz-Telles  F, Bonifaz  A, Rossow  J, Chindamporn  A. Sporothrix and sporotrichosis. Encyclopedia Infect Immun. 2022;2:376–96. DOIGoogle Scholar
  33. Kamal Azam  NK, Selvarajah  GT, Santhanam  J, Abdul Razak  MF, Ginsapu  SJ, James  JE, et al. Molecular epidemiology of Sporothrix schenkii isolates in Malaysia. Med Mycol. 2020;58:617–25. DOIPubMedGoogle Scholar
  34. Yingchanakiat  K, Limsivilai  O, Sunpongsri  S, Niyomtham  W, Lugsomya  K, Yurayart  C. Phenotypic and genotypic characterization and antifungal susceptibility of Sporothrix schenckii sensu stricto isolated from a feline sporotrichosis outbreak in Bangkok, Thailand. J Fungi (Basel). 2023;9:590. DOIPubMedGoogle Scholar
  35. Sharma  R, Mahajan  VK, Singh Chauhan  P, Mehta  KS, Sharma  A, Sharma  J. The clinico-epidemiological characteristics and therapeutic experience of 152 patients with cutaneous sporotrichosis: a 10-year retrospective study from India. Int J Dermatol. 2021;60:99–106. DOIPubMedGoogle Scholar
  36. de Lima Barros  MB, Schubach  AO, de Vasconcellos Carvalhaes de Oliveira  R, Martins  EB, Teixeira  JL, Wanke  B. Treatment of cutaneous sporotrichosis with itraconazole—study of 645 patients. Clin Infect Dis. 2011;52:e200–6. DOIPubMedGoogle Scholar
  37. Brandolt  TM, Madrid  IM, Poester  VR, Sanchotene  KO, Basso  RP, Klafke  GB, et al. Human sporotrichosis: A zoonotic outbreak in southern Brazil, 2012-2017. Med Mycol. 2019;57:527–33. DOIPubMedGoogle Scholar
  38. Quintella  LP, Passos  SR, do Vale  AC, Galhardo  MC, Barros  MB, Cuzzi  T, et al. Histopathology of cutaneous sporotrichosis in Rio de Janeiro: a series of 119 consecutive cases. J Cutan Pathol. 2011;38:25–32. DOIPubMedGoogle Scholar
  39. Tang  MM, Tang  JJ, Gill  P, Chang  CC, Baba  R. Cutaneous sporotrichosis: a six-year review of 19 cases in a tertiary referral center in Malaysia. Int J Dermatol. 2012;51:702–8. DOIPubMedGoogle Scholar
  40. Lloret  A, Hartmann  K, Pennisi  MG, Ferrer  L, Addie  D, Belák  S, et al. Sporotrichosis in cats: ABCD guidelines on prevention and management. J Feline Med Surg. 2013;15:619–23. DOIPubMedGoogle Scholar
  41. Carrada-Bravo  T, Olvera-Macías  MI. New observations on the ecology and epidemiology of Sporothrix schenckii and sporotrichosis 2. Ecological niches of S. schenckii and zoonotic outbreaks. Rev Mex Patol Clin Med Lab. 2013;60:5–24.
  42. Accardi  G, Caruso  C. Immune-inflammatory responses in the elderly: an update. Immun Ageing. 2018;15:11. DOIPubMedGoogle Scholar
  43. Fuentes  E, Fuentes  M, Alarcón  M, Palomo  I. Immune system dysfunction in the elderly. An Acad Bras Cienc. 2017;89:285–99. DOIPubMedGoogle Scholar
  44. Rodrigues  AM, de Melo Teixeira  M, de Hoog  GS, Schubach  TM, Pereira  SA, Fernandes  GF, et al. Phylogenetic analysis reveals a high prevalence of Sporothrix brasiliensis in feline sporotrichosis outbreaks. PLoS Negl Trop Dis. 2013;7:e2281. DOIPubMedGoogle Scholar
  45. Heninger  E, Hogan  LH, Karman  J, Macvilay  S, Hill  B, Woods  JP, et al. Characterization of the Histoplasma capsulatum-induced granuloma. J Immunol. 2006;177:3303–13. DOIPubMedGoogle Scholar
  46. Collette  JR, Lorenz  MC. Mechanisms of immune evasion in fungal pathogens. Curr Opin Microbiol. 2011;14:668–75. DOIPubMedGoogle Scholar
  47. Romani  L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:1–23. DOIPubMedGoogle Scholar
  48. Etchecopaz  A, Toscanini  MA, Gisbert  A, Mas  J, Scarpa  M, Iovannitti  CA, et al. Sporothrix brasiliensis: a review of an emerging South American fungal pathogen, its related disease, presentation and spread in Argentina. J Fungi (Basel). 2021;7:170. DOIPubMedGoogle Scholar
  49. Restrepo  A, Robledo  J, Gómez  I, Tabares  AM, Gutiérrez  R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol. 1986;122:413–7. DOIPubMedGoogle Scholar
  50. Sharkey-Mathis  PK, Kauffman  CA, Graybill  JR, Stevens  DA, Hostetler  JS, Cloud  G, et al.; NIAID Mycoses Study Group. Treatment of sporotrichosis with itraconazole. Am J Med. 1993;95:279–85. DOIPubMedGoogle Scholar

Main Article

Page created: September 24, 2024
Page updated: November 26, 2024
Page reviewed: November 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external